| Category | Name | IntersectionWithQuery | PValue | GenesInTerm | GenesInQuery | GenesInTermInQuery | ID |
|---|---|---|---|---|---|---|---|
| GeneOntologyMolecularFunction | glutamate-gated calcium ion channel activity | 1.70e-07 | 8 | 30 | 3 | GO:0022849 | |
| GeneOntologyMolecularFunction | NMDA glutamate receptor activity | 1.70e-07 | 8 | 30 | 3 | GO:0004972 | |
| GeneOntologyMolecularFunction | glutamate-gated receptor activity | 2.05e-06 | 17 | 30 | 3 | GO:0004970 | |
| GeneOntologyMolecularFunction | transmembrane signaling receptor activity | TMEM63B RRH OR2AG2 LIFR OR2S2 ERBB4 ABCA1 GRIN2A GRIN2C GRIN2D GPR33 | 2.18e-06 | 1353 | 30 | 11 | GO:0004888 |
| GeneOntologyMolecularFunction | glutamate receptor activity | 8.74e-06 | 27 | 30 | 3 | GO:0008066 | |
| GeneOntologyMolecularFunction | sphingolipid floppase activity | 1.31e-05 | 4 | 30 | 2 | GO:0046623 | |
| GeneOntologyMolecularFunction | ligand-gated calcium channel activity | 1.34e-05 | 31 | 30 | 3 | GO:0099604 | |
| GeneOntologyMolecularFunction | ligand-gated monoatomic cation channel activity | 5.51e-05 | 140 | 30 | 4 | GO:0099094 | |
| GeneOntologyMolecularFunction | transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potential | 8.48e-05 | 57 | 30 | 3 | GO:1904315 | |
| GeneOntologyMolecularFunction | neurotransmitter receptor activity involved in regulation of postsynaptic membrane potential | 9.88e-05 | 60 | 30 | 3 | GO:0099529 | |
| GeneOntologyMolecularFunction | transmitter-gated channel activity | 1.26e-04 | 65 | 30 | 3 | GO:0022835 | |
| GeneOntologyMolecularFunction | transmitter-gated monoatomic ion channel activity | 1.26e-04 | 65 | 30 | 3 | GO:0022824 | |
| GeneOntologyMolecularFunction | ligand-gated monoatomic ion channel activity | 1.90e-04 | 193 | 30 | 4 | GO:0015276 | |
| GeneOntologyMolecularFunction | postsynaptic neurotransmitter receptor activity | 1.92e-04 | 75 | 30 | 3 | GO:0098960 | |
| GeneOntologyMolecularFunction | glutamate binding | 1.96e-04 | 14 | 30 | 2 | GO:0016595 | |
| GeneOntologyMolecularFunction | ligand-gated channel activity | 2.06e-04 | 197 | 30 | 4 | GO:0022834 | |
| GeneOntologyMolecularFunction | extracellular ligand-gated monoatomic ion channel activity | 2.08e-04 | 77 | 30 | 3 | GO:0005230 | |
| GeneOntologyMolecularFunction | floppase activity | 2.58e-04 | 16 | 30 | 2 | GO:0140328 | |
| GeneOntologyMolecularFunction | sphingolipid transporter activity | 4.08e-04 | 20 | 30 | 2 | GO:0046624 | |
| GeneOntologyMolecularFunction | neurotransmitter receptor activity | 4.48e-04 | 100 | 30 | 3 | GO:0030594 | |
| GeneOntologyMolecularFunction | amino acid transmembrane transporter activity | 5.17e-04 | 105 | 30 | 3 | GO:0015171 | |
| GeneOntologyMolecularFunction | ligand-gated monoatomic ion channel activity involved in regulation of presynaptic membrane potential | 5.90e-04 | 24 | 30 | 2 | GO:0099507 | |
| GeneOntologyMolecularFunction | ATPase-coupled intramembrane lipid transporter activity | 8.05e-04 | 28 | 30 | 2 | GO:0140326 | |
| GeneOntologyMolecularFunction | calcium channel activity | 9.41e-04 | 129 | 30 | 3 | GO:0005262 | |
| GeneOntologyMolecularFunction | calcium ion transmembrane transporter activity | 1.48e-03 | 151 | 30 | 3 | GO:0015085 | |
| GeneOntologyMolecularFunction | gated channel activity | 1.49e-03 | 334 | 30 | 4 | GO:0022836 | |
| GeneOntologyMolecularFunction | monoatomic cation channel activity | 1.65e-03 | 343 | 30 | 4 | GO:0005261 | |
| GeneOntologyMolecularFunction | ABC-type transporter activity | 2.46e-03 | 49 | 30 | 2 | GO:0140359 | |
| GeneOntologyMolecularFunction | voltage-gated monoatomic ion channel activity | 2.52e-03 | 182 | 30 | 3 | GO:0005244 | |
| GeneOntologyMolecularFunction | voltage-gated channel activity | 2.60e-03 | 184 | 30 | 3 | GO:0022832 | |
| GeneOntologyMolecularFunction | intramembrane lipid transporter activity | 2.66e-03 | 51 | 30 | 2 | GO:0140303 | |
| GeneOntologyMolecularFunction | carboxylic acid transmembrane transporter activity | 3.63e-03 | 207 | 30 | 3 | GO:0046943 | |
| GeneOntologyMolecularFunction | organic acid transmembrane transporter activity | 3.68e-03 | 208 | 30 | 3 | GO:0005342 | |
| GeneOntologyMolecularFunction | monoatomic ion channel activity | 4.70e-03 | 459 | 30 | 4 | GO:0005216 | |
| GeneOntologyMolecularFunction | amino acid binding | 5.37e-03 | 73 | 30 | 2 | GO:0016597 | |
| GeneOntologyMolecularFunction | transmembrane transporter activity | 7.34e-03 | 1180 | 30 | 6 | GO:0022857 | |
| GeneOntologyMolecularFunction | channel activity | 7.53e-03 | 525 | 30 | 4 | GO:0015267 | |
| GeneOntologyMolecularFunction | passive transmembrane transporter activity | 7.58e-03 | 526 | 30 | 4 | GO:0022803 | |
| GeneOntologyMolecularFunction | organic anion transmembrane transporter activity | 9.47e-03 | 293 | 30 | 3 | GO:0008514 | |
| GeneOntologyMolecularFunction | transporter activity | 1.11e-02 | 1289 | 30 | 6 | GO:0005215 | |
| GeneOntologyMolecularFunction | ATPase binding | 1.14e-02 | 108 | 30 | 2 | GO:0051117 | |
| GeneOntologyMolecularFunction | ATPase-coupled transmembrane transporter activity | 1.16e-02 | 109 | 30 | 2 | GO:0042626 | |
| GeneOntologyMolecularFunction | inorganic cation transmembrane transporter activity | 1.38e-02 | 627 | 30 | 4 | GO:0022890 | |
| GeneOntologyBiologicalProcess | excitatory chemical synaptic transmission | 1.70e-06 | 16 | 31 | 3 | GO:0098976 | |
| GeneOntologyBiologicalProcess | ionotropic glutamate receptor signaling pathway | 8.77e-06 | 27 | 31 | 3 | GO:0035235 | |
| GeneOntologyBiologicalProcess | directional locomotion | 1.31e-05 | 4 | 31 | 2 | GO:0033058 | |
| GeneOntologyBiologicalProcess | sphingolipid translocation | 2.18e-05 | 5 | 31 | 2 | GO:0099039 | |
| GeneOntologyBiologicalProcess | ligand-gated ion channel signaling pathway | 2.92e-05 | 40 | 31 | 3 | GO:1990806 | |
| GeneOntologyBiologicalProcess | startle response | 3.15e-05 | 41 | 31 | 3 | GO:0001964 | |
| GeneOntologyBiologicalProcess | positive regulation of excitatory postsynaptic potential | 3.64e-05 | 43 | 31 | 3 | GO:2000463 | |
| GeneOntologyBiologicalProcess | positive regulation of synaptic transmission, glutamatergic | 3.64e-05 | 43 | 31 | 3 | GO:0051968 | |
| GeneOntologyBiologicalProcess | glutamate receptor signaling pathway | 9.44e-05 | 59 | 31 | 3 | GO:0007215 | |
| GeneOntologyBiologicalProcess | modulation of excitatory postsynaptic potential | 1.26e-04 | 65 | 31 | 3 | GO:0098815 | |
| GeneOntologyBiologicalProcess | protein localization to postsynaptic membrane | 2.09e-04 | 77 | 31 | 3 | GO:1903539 | |
| GeneOntologyBiologicalProcess | regulation of transmembrane transport | 2.12e-04 | 589 | 31 | 6 | GO:0034762 | |
| GeneOntologyBiologicalProcess | protein localization to postsynapse | 2.34e-04 | 80 | 31 | 3 | GO:0062237 | |
| GeneOntologyBiologicalProcess | regulation of neuronal synaptic plasticity | 2.60e-04 | 83 | 31 | 3 | GO:0048168 | |
| GeneOntologyBiologicalProcess | regulation of synaptic transmission, glutamatergic | 3.53e-04 | 92 | 31 | 3 | GO:0051966 | |
| GeneOntologyBiologicalProcess | positive regulation of synaptic transmission | 3.93e-04 | 233 | 31 | 4 | GO:0050806 | |
| GeneOntologyBiologicalProcess | regulation of phospholipid biosynthetic process | 4.51e-04 | 21 | 31 | 2 | GO:0071071 | |
| GeneOntologyBiologicalProcess | surfactant homeostasis | 6.42e-04 | 25 | 31 | 2 | GO:0043129 | |
| GeneOntologyBiologicalProcess | protein localization to synapse | 6.77e-04 | 115 | 31 | 3 | GO:0035418 | |
| GeneOntologyBiologicalProcess | detection of mechanical stimulus involved in sensory perception of pain | 6.95e-04 | 26 | 31 | 2 | GO:0050966 | |
| GeneOntologyBiologicalProcess | excitatory postsynaptic potential | 9.67e-04 | 130 | 31 | 3 | GO:0060079 | |
| GeneOntologyBiologicalProcess | synaptic transmission, glutamatergic | 1.01e-03 | 132 | 31 | 3 | GO:0035249 | |
| GeneOntologyCellularComponent | NMDA selective glutamate receptor complex | 2.47e-07 | 9 | 31 | 3 | GO:0017146 | |
| GeneOntologyCellularComponent | endoplasmic reticulum membrane | GPAT3 PDIA5 ABCA1 GRIN2A GRIN2C GRIN2D ELOVL6 ARL6IP1 ALG9 SYNE2 PHTF1 | 1.30e-06 | 1293 | 31 | 11 | GO:0005789 |
| GeneOntologyCellularComponent | endoplasmic reticulum subcompartment | GPAT3 PDIA5 ABCA1 GRIN2A GRIN2C GRIN2D ELOVL6 ARL6IP1 ALG9 SYNE2 PHTF1 | 1.36e-06 | 1299 | 31 | 11 | GO:0098827 |
| GeneOntologyCellularComponent | nuclear outer membrane-endoplasmic reticulum membrane network | GPAT3 PDIA5 ABCA1 GRIN2A GRIN2C GRIN2D ELOVL6 ARL6IP1 ALG9 SYNE2 PHTF1 | 1.68e-06 | 1327 | 31 | 11 | GO:0042175 |
| GeneOntologyCellularComponent | ionotropic glutamate receptor complex | 4.02e-05 | 45 | 31 | 3 | GO:0008328 | |
| GeneOntologyCellularComponent | neurotransmitter receptor complex | 5.52e-05 | 50 | 31 | 3 | GO:0098878 | |
| GeneOntologyCellularComponent | postsynaptic density membrane | 8.23e-05 | 157 | 31 | 4 | GO:0098839 | |
| GeneOntologyCellularComponent | postsynaptic specialization membrane | 2.13e-04 | 201 | 31 | 4 | GO:0099634 | |
| GeneOntologyCellularComponent | receptor complex | 1.52e-03 | 581 | 31 | 5 | GO:0043235 | |
| GeneOntologyCellularComponent | postsynaptic membrane | 2.89e-03 | 405 | 31 | 4 | GO:0045211 | |
| Domain | Iontro_rcpt | 3.32e-06 | 18 | 31 | 3 | IPR001320 | |
| Domain | Lig_chan | 3.32e-06 | 18 | 31 | 3 | PF00060 | |
| Domain | Lig_chan-Glu_bd | 3.32e-06 | 18 | 31 | 3 | PF10613 | |
| Domain | PBPe | 3.32e-06 | 18 | 31 | 3 | SM00079 | |
| Domain | Iono_rcpt_met | 3.32e-06 | 18 | 31 | 3 | IPR001508 | |
| Domain | Glu/Gly-bd | 3.32e-06 | 18 | 31 | 3 | IPR019594 | |
| Domain | Lig_chan-Glu_bd | 3.32e-06 | 18 | 31 | 3 | SM00918 | |
| Domain | NMDAR2_C | 7.99e-06 | 3 | 31 | 2 | PF10565 | |
| Domain | NMDAR2_C | 7.99e-06 | 3 | 31 | 2 | IPR018884 | |
| Domain | ANF_receptor | 3.10e-05 | 37 | 31 | 3 | PF01094 | |
| Domain | ANF_lig-bd_rcpt | 3.10e-05 | 37 | 31 | 3 | IPR001828 | |
| Domain | Peripla_BP_I | 3.63e-05 | 39 | 31 | 3 | IPR028082 | |
| Domain | ABC_A | 1.74e-04 | 12 | 31 | 2 | IPR026082 | |
| Domain | ABC_transporter_CS | 2.20e-03 | 42 | 31 | 2 | IPR017871 | |
| Domain | ABC_TRANSPORTER_2 | 2.87e-03 | 48 | 31 | 2 | PS50893 | |
| Domain | ABC_tran | 2.87e-03 | 48 | 31 | 2 | PF00005 | |
| Domain | ABC_TRANSPORTER_1 | 2.99e-03 | 49 | 31 | 2 | PS00211 | |
| Domain | ABC_transporter-like | 3.11e-03 | 50 | 31 | 2 | IPR003439 | |
| Pathway | REACTOME_ASSEMBLY_AND_CELL_SURFACE_PRESENTATION_OF_NMDA_RECEPTORS | 4.92e-08 | 5 | 25 | 3 | MM15655 | |
| Pathway | KEGG_MEDICUS_REFERENCE_TRANSPORT_OF_CALCIUM | 4.92e-08 | 5 | 25 | 3 | M47667 | |
| Pathway | REACTOME_LONG_TERM_POTENTIATION | 6.66e-08 | 23 | 25 | 4 | M27949 | |
| Pathway | KEGG_MEDICUS_VARIANT_MUTATION_CAUSED_ABERRANT_PDYN_TO_TRANSPORT_OF_CALCIUM | 9.82e-08 | 6 | 25 | 3 | M47668 | |
| Pathway | KEGG_MEDICUS_REFERENCE_CA2_ENTRY_LIGAND_GATED_CA2_CHANNEL | 1.07e-06 | 12 | 25 | 3 | M47953 | |
| Pathway | WP_NOCGMPPKG_MEDIATED_NEUROPROTECTION | 1.30e-06 | 47 | 25 | 4 | M39531 | |
| Pathway | KEGG_MEDICUS_VARIANT_MUTATION_CAUSED_ABERRANT_ABETA_TO_TRANSPORT_OF_CALCIUM | 2.21e-06 | 15 | 25 | 3 | M47691 | |
| Pathway | WP_PHOSPHODIESTERASES_IN_NEURONAL_FUNCTION | 2.47e-06 | 55 | 25 | 4 | M39763 | |
| Pathway | KEGG_MEDICUS_VARIANT_SCRAPIE_CONFORMATION_PRPSC_TO_TRANSPORT_OF_CALCIUM | 3.95e-06 | 18 | 25 | 3 | M47761 | |
| Pathway | WP_NRXN1_DELETION_SYNDROME | 3.95e-06 | 18 | 25 | 3 | M48098 | |
| Pathway | KEGG_MEDICUS_VARIANT_MUTATION_CAUSED_ABERRANT_HTT_TO_TRANSPORT_OF_CALCIUM | 4.69e-06 | 19 | 25 | 3 | M47677 | |
| Pathway | BIOCARTA_NOS1_PATHWAY | 5.51e-06 | 20 | 25 | 3 | MM1445 | |
| Pathway | REACTOME_SYNAPTIC_ADHESION_LIKE_MOLECULES | 5.51e-06 | 20 | 25 | 3 | MM15485 | |
| Pathway | REACTOME_SYNAPTIC_ADHESION_LIKE_MOLECULES | 6.42e-06 | 21 | 25 | 3 | M27736 | |
| Pathway | BIOCARTA_NOS1_PATHWAY | 6.42e-06 | 21 | 25 | 3 | M11650 | |
| Pathway | REACTOME_UNBLOCKING_OF_NMDA_RECEPTORS_GLUTAMATE_BINDING_AND_ACTIVATION | 6.42e-06 | 21 | 25 | 3 | M838 | |
| Pathway | REACTOME_NEGATIVE_REGULATION_OF_NMDA_RECEPTOR_MEDIATED_NEURONAL_TRANSMISSION | 6.42e-06 | 21 | 25 | 3 | M27944 | |
| Pathway | REACTOME_UNBLOCKING_OF_NMDA_RECEPTORS_GLUTAMATE_BINDING_AND_ACTIVATION | 7.42e-06 | 22 | 25 | 3 | MM15104 | |
| Pathway | REACTOME_ACTIVATION_OF_NMDA_RECEPTORS_AND_POSTSYNAPTIC_EVENTS | 2.11e-05 | 94 | 25 | 4 | M2843 | |
| Pathway | WP_DISRUPTION_OF_POSTSYNAPTIC_SIGNALING_BY_CNV | 2.60e-05 | 33 | 25 | 3 | M39875 | |
| Pathway | REACTOME_ACTIVATION_OF_NMDA_RECEPTORS_AND_POSTSYNAPTIC_EVENTS | 3.11e-05 | 35 | 25 | 3 | MM15109 | |
| Pathway | WP_VITAMIN_DSENSITIVE_CALCIUM_SIGNALING_IN_DEPRESSION | 3.38e-05 | 36 | 25 | 3 | M39831 | |
| Pathway | REACTOME_ASSEMBLY_AND_CELL_SURFACE_PRESENTATION_OF_NMDA_RECEPTORS | 6.22e-05 | 44 | 25 | 3 | M27934 | |
| Pathway | WP_SYNAPTIC_SIGNALING_ASSOCIATED_WITH_AUTISM_SPECTRUM_DISORDER | 9.14e-05 | 50 | 25 | 3 | M39822 | |
| Pathway | KEGG_AMYOTROPHIC_LATERAL_SCLEROSIS_ALS | 1.09e-04 | 53 | 25 | 3 | M3812 | |
| Pathway | REACTOME_NEUREXINS_AND_NEUROLIGINS | 1.28e-04 | 56 | 25 | 3 | M27616 | |
| Pathway | REACTOME_PROTEIN_PROTEIN_INTERACTIONS_AT_SYNAPSES | 2.19e-04 | 67 | 25 | 3 | MM15327 | |
| Pathway | KEGG_LONG_TERM_POTENTIATION | 2.49e-04 | 70 | 25 | 3 | M3115 | |
| Pathway | KEGG_CALCIUM_SIGNALING_PATHWAY | 2.53e-04 | 178 | 25 | 4 | M2890 | |
| Pathway | WP_ALZHEIMERS_DISEASE | 2.94e-04 | 74 | 25 | 3 | MM15962 | |
| Pathway | REACTOME_NEUROTRANSMITTER_RECEPTORS_AND_POSTSYNAPTIC_SIGNAL_TRANSMISSION | 4.32e-04 | 205 | 25 | 4 | M752 | |
| Pathway | REACTOME_PROTEIN_PROTEIN_INTERACTIONS_AT_SYNAPSES | 4.73e-04 | 87 | 25 | 3 | M27617 | |
| Pathway | WP_MTHFR_DEFICIENCY | 8.14e-04 | 24 | 25 | 2 | M39755 | |
| Pathway | REACTOME_TRANSMISSION_ACROSS_CHEMICAL_SYNAPSES | 1.21e-03 | 270 | 25 | 4 | M15514 | |
| Pathway | WP_NEUROINFLAMMATION_AND_GLUTAMATERGIC_SIGNALING | 1.88e-03 | 140 | 25 | 3 | M42572 | |
| Pathway | REACTOME_NEUROTRANSMITTER_RECEPTORS_AND_POSTSYNAPTIC_SIGNAL_TRANSMISSION | 2.04e-03 | 144 | 25 | 3 | MM14501 | |
| Pathway | KEGG_ABC_TRANSPORTERS | 2.73e-03 | 44 | 25 | 2 | M11911 | |
| Pathway | KEGG_ALZHEIMERS_DISEASE | 3.05e-03 | 166 | 25 | 3 | M16024 | |
| Pathway | WP_RETT_SYNDROME | 3.24e-03 | 48 | 25 | 2 | M39759 | |
| Pathway | WP_GPCRS_CLASS_A_RHODOPSINLIKE | 4.20e-03 | 186 | 25 | 3 | MM15994 | |
| Pathway | REACTOME_NEURONAL_SYSTEM | 5.54e-03 | 411 | 25 | 4 | M735 | |
| Pathway | REACTOME_TRANSMISSION_ACROSS_CHEMICAL_SYNAPSES | 5.96e-03 | 211 | 25 | 3 | MM14502 | |
| Pathway | WP_MELANOMA | 6.40e-03 | 68 | 25 | 2 | M39811 | |
| Pubmed | 6.41e-10 | 3 | 31 | 3 | 9718984 | ||
| Pubmed | 6.41e-10 | 3 | 31 | 3 | 9480759 | ||
| Pubmed | 2.56e-09 | 4 | 31 | 3 | 8699248 | ||
| Pubmed | 2.56e-09 | 4 | 31 | 3 | 9768843 | ||
| Pubmed | Structural insights into assembly and function of GluN1-2C, GluN1-2A-2C, and GluN1-2D NMDARs. | 2.56e-09 | 4 | 31 | 3 | 36309015 | |
| Pubmed | 6.40e-09 | 5 | 31 | 3 | 26875626 | ||
| Pubmed | 6.40e-09 | 5 | 31 | 3 | 26919761 | ||
| Pubmed | Distinct distributions of five NMDA receptor channel subunit mRNAs in the brainstem. | 6.40e-09 | 5 | 31 | 3 | 7518475 | |
| Pubmed | Distinct spatiotemporal expressions of five NMDA receptor channel subunit mRNAs in the cerebellum. | 6.40e-09 | 5 | 31 | 3 | 7518474 | |
| Pubmed | 6.40e-09 | 5 | 31 | 3 | 9147327 | ||
| Pubmed | Differential distributions of the NMDA receptor channel subunit mRNAs in the mouse retina. | 6.40e-09 | 5 | 31 | 3 | 7510577 | |
| Pubmed | 6.40e-09 | 5 | 31 | 3 | 8015722 | ||
| Pubmed | 6.40e-09 | 5 | 31 | 3 | 15003177 | ||
| Pubmed | 6.40e-09 | 5 | 31 | 3 | 7723623 | ||
| Pubmed | 6.40e-09 | 5 | 31 | 3 | 8756432 | ||
| Pubmed | 6.40e-09 | 5 | 31 | 3 | 12082569 | ||
| Pubmed | 6.40e-09 | 5 | 31 | 3 | 21945132 | ||
| Pubmed | 6.40e-09 | 5 | 31 | 3 | 18233995 | ||
| Pubmed | 6.40e-09 | 5 | 31 | 3 | 11488959 | ||
| Pubmed | Developmental changes in distribution of NMDA receptor channel subunit mRNAs. | 6.40e-09 | 5 | 31 | 3 | 1493227 | |
| Pubmed | 6.40e-09 | 5 | 31 | 3 | 8036251 | ||
| Pubmed | NMDA receptor activation by HIV-Tat protein is clade dependent. | 6.40e-09 | 5 | 31 | 3 | 19020013 | |
| Pubmed | 6.40e-09 | 5 | 31 | 3 | 7929904 | ||
| Pubmed | Cortical consequences of HIV-1 Tat exposure in rats are enhanced by chronic cocaine. | 1.28e-08 | 6 | 31 | 3 | 25760043 | |
| Pubmed | 1.28e-08 | 6 | 31 | 3 | 23665428 | ||
| Pubmed | 1.28e-08 | 6 | 31 | 3 | 8996814 | ||
| Pubmed | Importance of the intracellular domain of NR2 subunits for NMDA receptor function in vivo. | 1.28e-08 | 6 | 31 | 3 | 9458051 | |
| Pubmed | 1.28e-08 | 6 | 31 | 3 | 15317856 | ||
| Pubmed | 2.24e-08 | 7 | 31 | 3 | 12103442 | ||
| Pubmed | 2.24e-08 | 7 | 31 | 3 | 23267846 | ||
| Pubmed | 2.24e-08 | 7 | 31 | 3 | 19036954 | ||
| Pubmed | 2.24e-08 | 7 | 31 | 3 | 22833210 | ||
| Pubmed | HIV immune complexes prevent excitotoxicity by interaction with NMDA receptors. | 2.24e-08 | 7 | 31 | 3 | 22940423 | |
| Pubmed | Direct cytotoxicity of HIV-1 envelope protein gp120 on human NT neurons. | 3.58e-08 | 8 | 31 | 3 | 8804048 | |
| Pubmed | 3.58e-08 | 8 | 31 | 3 | 17360663 | ||
| Pubmed | 3.58e-08 | 8 | 31 | 3 | 8724036 | ||
| Pubmed | 3.58e-08 | 8 | 31 | 3 | 8845955 | ||
| Pubmed | 3.58e-08 | 8 | 31 | 3 | 8822372 | ||
| Pubmed | 3.58e-08 | 8 | 31 | 3 | 21106831 | ||
| Pubmed | 3.58e-08 | 8 | 31 | 3 | 8563977 | ||
| Pubmed | HIV-1 gp120-induced neurotoxicity to midbrain dopamine cultures. | 3.58e-08 | 8 | 31 | 3 | 8821747 | |
| Pubmed | 3.58e-08 | 8 | 31 | 3 | 10448428 | ||
| Pubmed | 3.58e-08 | 8 | 31 | 3 | 7695237 | ||
| Pubmed | 3.58e-08 | 8 | 31 | 3 | 8955056 | ||
| Pubmed | 3.58e-08 | 8 | 31 | 3 | 10555109 | ||
| Pubmed | 5.37e-08 | 9 | 31 | 3 | 17526495 | ||
| Pubmed | D1/NMDA receptors and concurrent methamphetamine+ HIV-1 Tat neurotoxicity. | 5.37e-08 | 9 | 31 | 3 | 22552781 | |
| Pubmed | 5.37e-08 | 9 | 31 | 3 | 21670103 | ||
| Pubmed | 5.37e-08 | 9 | 31 | 3 | 21491143 | ||
| Pubmed | 5.37e-08 | 9 | 31 | 3 | 16554481 | ||
| Pubmed | 5.37e-08 | 9 | 31 | 3 | 9892651 | ||
| Pubmed | 7.66e-08 | 10 | 31 | 3 | 19332541 | ||
| Pubmed | 1.05e-07 | 11 | 31 | 3 | 8581564 | ||
| Pubmed | HIV-1 Tat-mediated apoptosis in human blood-retinal barrier-associated cells. | 1.05e-07 | 11 | 31 | 3 | 24739951 | |
| Pubmed | 1.05e-07 | 11 | 31 | 3 | 9647694 | ||
| Pubmed | Effects of SDF-1alpha and gp120IIIB on apoptotic pathways in SK-N-SH neuroblastoma cells. | 1.05e-07 | 11 | 31 | 3 | 16481105 | |
| Pubmed | 1.40e-07 | 12 | 31 | 3 | 12815021 | ||
| Pubmed | 1.40e-07 | 12 | 31 | 3 | 11937501 | ||
| Pubmed | 1.40e-07 | 12 | 31 | 3 | 8665664 | ||
| Pubmed | 2.32e-07 | 14 | 31 | 3 | 15749123 | ||
| Pubmed | Neurotoxicity of human immunodeficiency virus-1: viral proteins and axonal transport. | 2.90e-07 | 15 | 31 | 3 | 21948112 | |
| Pubmed | Neuronal interleukin-16 (NIL-16): a dual function PDZ domain protein. | 2.90e-07 | 15 | 31 | 3 | 10479680 | |
| Pubmed | 4.32e-07 | 17 | 31 | 3 | 24086760 | ||
| Pubmed | Gene structure and chromosomal localization of the mouse NMDA receptor channel subunits. | 5.18e-07 | 18 | 31 | 3 | 9011744 | |
| Pubmed | Attenuation of focal cerebral infarct in mice lacking NMDA receptor subunit NR2C. | 7.69e-07 | 2 | 31 | 2 | 9512392 | |
| Pubmed | NMDA receptor subtypes at autaptic synapses of cerebellar granule neurons. | 7.69e-07 | 2 | 31 | 2 | 16885526 | |
| Pubmed | Conditioned eyeblink response is impaired in mutant mice lacking NMDA receptor subunit NR2A. | 7.69e-07 | 2 | 31 | 2 | 9427357 | |
| Pubmed | 7.69e-07 | 2 | 31 | 2 | 29651654 | ||
| Pubmed | 7.69e-07 | 2 | 31 | 2 | 12427824 | ||
| Pubmed | 7.69e-07 | 2 | 31 | 2 | 31110197 | ||
| Pubmed | 7.69e-07 | 2 | 31 | 2 | 21060893 | ||
| Pubmed | 7.69e-07 | 2 | 31 | 2 | 25788577 | ||
| Pubmed | ABCA2 is a strong genetic risk factor for early-onset Alzheimer's disease. | 7.69e-07 | 2 | 31 | 2 | 15649702 | |
| Pubmed | 7.69e-07 | 2 | 31 | 2 | 16207881 | ||
| Pubmed | 7.69e-07 | 2 | 31 | 2 | 16189474 | ||
| Pubmed | Cloning of two novel ABC transporters mapping on human chromosome 9. | 7.69e-07 | 2 | 31 | 2 | 8088782 | |
| Pubmed | 7.69e-07 | 2 | 31 | 2 | 10972963 | ||
| Pubmed | Characterization of the glutamatergic system for induction and maintenance of allodynia. | 7.69e-07 | 2 | 31 | 2 | 11259776 | |
| Pubmed | 7.69e-07 | 2 | 31 | 2 | 29317596 | ||
| Pubmed | Absence of prostaglandin E2-induced hyperalgesia in NMDA receptor epsilon subunit knockout mice. | 7.69e-07 | 2 | 31 | 2 | 9113374 | |
| Pubmed | 7.69e-07 | 2 | 31 | 2 | 10771345 | ||
| Pubmed | 7.69e-07 | 2 | 31 | 2 | 17548218 | ||
| Pubmed | 7.69e-07 | 2 | 31 | 2 | 35057644 | ||
| Pubmed | 7.69e-07 | 2 | 31 | 2 | 8987814 | ||
| Pubmed | 7.69e-07 | 2 | 31 | 2 | 33766086 | ||
| Pubmed | Characterization of N-methyl-D-aspartate receptor subunits responsible for postoperative pain. | 7.69e-07 | 2 | 31 | 2 | 15496298 | |
| Pubmed | 7.69e-07 | 2 | 31 | 2 | 10970803 | ||
| Pubmed | 7.69e-07 | 2 | 31 | 2 | 11422443 | ||
| Pubmed | 7.69e-07 | 2 | 31 | 2 | 1282354 | ||
| Pubmed | 7.69e-07 | 2 | 31 | 2 | 31786200 | ||
| Pubmed | 8.44e-07 | 21 | 31 | 3 | 22114277 | ||
| Pubmed | Glutamate can act as a signaling molecule in mouse preimplantation embryos†. | 1.28e-06 | 24 | 31 | 3 | 35746896 | |
| Pubmed | Mechanisms of prionSc- and HIV-1 gp120 induced neuronal cell death. | 1.64e-06 | 26 | 31 | 3 | 9745929 | |
| Pubmed | 2.31e-06 | 3 | 31 | 2 | 15519237 | ||
| Pubmed | 2.31e-06 | 3 | 31 | 2 | 35867797 | ||
| Pubmed | 2.31e-06 | 3 | 31 | 2 | 22486492 | ||
| Pubmed | Cloning and expression of the epsilon 4 subunit of the NMDA receptor channel. | 2.31e-06 | 3 | 31 | 2 | 1385220 | |
| Pubmed | 2.31e-06 | 3 | 31 | 2 | 18685090 | ||
| Pubmed | 2.31e-06 | 3 | 31 | 2 | 17350656 | ||
| Pubmed | 2.31e-06 | 3 | 31 | 2 | 8267632 | ||
| Interaction | DLG2 interactions | 5.87e-06 | 83 | 29 | 4 | int:DLG2 | |
| Interaction | DLG3 interactions | 3.57e-05 | 131 | 29 | 4 | int:DLG3 | |
| Cytoband | 4q25 | 9.49e-04 | 67 | 31 | 2 | 4q25 | |
| Cytoband | Ensembl 112 genes in cytogenetic band chr4q25 | 1.74e-03 | 91 | 31 | 2 | chr4q25 | |
| GeneFamily | Glutamate ionotropic receptor NMDA type subunits | 4.04e-08 | 7 | 20 | 3 | 1201 | |
| GeneFamily | ATP binding cassette subfamily A | 1.05e-04 | 14 | 20 | 2 | 805 | |
| GeneFamily | Olfactory receptors, family 2 | 6.84e-03 | 113 | 20 | 2 | 149 | |
| ToppCell | Children_(3_yrs)-Immune-natural_killer_cell-D032|Children_(3_yrs) / Lineage, Cell type, age group and donor | 5.47e-06 | 174 | 30 | 4 | 33d6b81f31bfcb9c4b30206d88e20b9a94fba4a2 | |
| ToppCell | Adult-Immune-natural_killer_cell-D175|Adult / Lineage, Cell type, age group and donor | 6.26e-06 | 180 | 30 | 4 | fc59e28f39e7d4fb1bcc7205202cf39224b70d7b | |
| ToppCell | Adult-Immune-natural_killer_cell|Adult / Lineage, Cell type, age group and donor | 7.91e-06 | 191 | 30 | 4 | 758ec27e47d7662a5175305e98a1506c6859dbf7 | |
| ToppCell | Children_(3_yrs)-Immune-natural_killer_cell|Children_(3_yrs) / Lineage, Cell type, age group and donor | 8.24e-06 | 193 | 30 | 4 | 1cb666375bc4e1b11a146d20896c9b5ae6fd0887 | |
| ToppCell | Children_(3_yrs)-Immune-T_lymphocyte-D139|Children_(3_yrs) / Lineage, Cell type, age group and donor | 8.41e-06 | 194 | 30 | 4 | 3d6f2d190dd50804afea299957cc44c2bb756134 | |
| ToppCell | renal_papilla_nuclei-Adult_normal_reference-Immune-Myeloid-Granulocytic-Mast_Cell|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group | 1.67e-04 | 160 | 30 | 3 | fe9970c160159b35f6599ed13c89cfb49264d554 | |
| ToppCell | facs-Pancreas-Exocrine-18m-Hematologic|Pancreas / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.70e-04 | 161 | 30 | 3 | f5821f551cf5c64c9f75cdb723492c87aac1ece0 | |
| ToppCell | facs-Pancreas-Exocrine-18m-Hematologic-leukocyte|Pancreas / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.70e-04 | 161 | 30 | 3 | 58a32a1033f379579697bda1bbf047a088e4a34f | |
| ToppCell | facs-Pancreas-Exocrine-18m-Hematologic-nan|Pancreas / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.70e-04 | 161 | 30 | 3 | 16f77e7a5444d2f2b210362816cd7a07b9b42af6 | |
| ToppCell | facs-Lung-ENDOMUCIN-18m-Lymphocytic-NK_cell|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.73e-04 | 162 | 30 | 3 | 5731f9514434296132df4bc86f78ce87b07cdeca | |
| ToppCell | facs-Lung-ENDOMUCIN-18m-Lymphocytic-Natural_Killer|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.73e-04 | 162 | 30 | 3 | 0321fc954ae4ad67ca438cbbc84632562d222188 | |
| ToppCell | 10x_3'_v3-tissue-resident_(10x_3'_v3)-lymphocytic-T_lymphocytic-effector_CD4-positive,_alpha-beta_T_cell|tissue-resident_(10x_3'_v3) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type | 1.93e-04 | 168 | 30 | 3 | 07be11b6f0f37106e219692db5795c6dd32807c9 | |
| ToppCell | Adult-Epithelial-alveolar_epithelial_cell_type_2/Club-like_(AT2/Club-like)-D231|Adult / Lineage, Cell type, age group and donor | 2.00e-04 | 170 | 30 | 3 | 269dee5abca9f6aa079f116f0d8f1d198604d9d4 | |
| ToppCell | Severe-Lymphoid-T-|Severe / Condition, Lineage, Cell class and cell subclass | 2.00e-04 | 170 | 30 | 3 | 5788e1158fde036937d41708e9db3222ca351eb1 | |
| ToppCell | 3'-Child09-12-SmallIntestine-Hematopoietic-T_cells-TRGV4_gdT|Child09-12 / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 2.00e-04 | 170 | 30 | 3 | 65c7ed586e7615203a59999549892ed466a89502 | |
| ToppCell | facs-Large_Intestine-Proximal-3m-Epithelial-Lgr5+_undifferentiated_cell_(Distal)|Large_Intestine / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.00e-04 | 170 | 30 | 3 | 833b4f44ea1fa673dfc6b43ce45a79fe68ae3b05 | |
| ToppCell | normal_Pleural_Fluid-T/NK_cells-Cytotoxic_CD8+_T|normal_Pleural_Fluid / Location, Cell class and cell subclass | 2.03e-04 | 171 | 30 | 3 | 6be81c20f4e962b414afcedfe478dd59c510d1e1 | |
| ToppCell | Mid-temporal_gyrus_(MTG)-Neuronal-Inh_GABAergic-i_Gaba_2-GABA_VIP_2-Inh_L1_VIP_PCDH20|Mid-temporal_gyrus_(MTG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 2.07e-04 | 172 | 30 | 3 | 35e961c88bfe79046533396912cedf00ca81db7b | |
| ToppCell | BL-critical-LOC-Lymphoid-PC|LOC / Location, Severity, dps_group, Lineage and Cell class of Upper airway (combined) | 2.10e-04 | 173 | 30 | 3 | 90700a876d997f7c0f7b3899dffcda7fdafee547 | |
| ToppCell | droplet-Marrow-nan-3m-Lymphocytic-NK_cell|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.17e-04 | 175 | 30 | 3 | cf53a15bfb37b6019e7052ffdf594a9ac040900e | |
| ToppCell | Somatosensory_Cortex_(S1)-Neuronal-Inh_GABAergic-i_Gaba_3-GABA_PVALB_1-Inh_L5-6_PVALB_STON2|Somatosensory_Cortex_(S1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 2.21e-04 | 176 | 30 | 3 | 682a1dfcc507ec540f5fadf08e872533ea9f0291 | |
| ToppCell | Somatosensory_Cortex_(S1)-Neuronal-Inh_GABAergic-i_Gaba_2-GABA_VIP_2-Inh_L1-3_VIP_GGH|Somatosensory_Cortex_(S1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 2.21e-04 | 176 | 30 | 3 | 23f930dac5247ea6d4124da33933d61ad6e089af | |
| ToppCell | Mid-temporal_gyrus_(MTG)-Neuronal-Inh_GABAergic-i_Gaba_3-GABA_PVALB_2-Inh_L1-6_PVALB_SCUBE3_(Chandelier_1)|Mid-temporal_gyrus_(MTG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 2.21e-04 | 176 | 30 | 3 | 95d5a4fdff1b9c715636684d22e06f8727ac0e7a | |
| ToppCell | Primary_Visual_cortex_(V1C)-Neuronal-Inh_GABAergic-i_Gaba_2-GABA_VIP_2-Inh_L1-3_VIP_ZNF322P1|Primary_Visual_cortex_(V1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 2.25e-04 | 177 | 30 | 3 | 84116796ca4c7007508c0f1a68a1135c7b922278 | |
| ToppCell | Mid-temporal_gyrus_(MTG)-Neuronal-Inh_GABAergic-i_Gaba_3-GABA_PVALB_1-Inh_L1-2_PVALB_TAC1|Mid-temporal_gyrus_(MTG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 2.29e-04 | 178 | 30 | 3 | 1985271984e6747941c8d2097d9c58f0260f021a | |
| ToppCell | Primary_Visual_cortex_(V1C)-Neuronal-Inh_GABAergic-i_Gaba_2-GABA_VIP_2|Primary_Visual_cortex_(V1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 2.29e-04 | 178 | 30 | 3 | 3c973aac16988e88f5677d3d695dd772ccfd6570 | |
| ToppCell | droplet-Limb_Muscle-MUSCLE-30m|Limb_Muscle / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.29e-04 | 178 | 30 | 3 | 01dafd19de04eff459253eaa9a35debf8f3deedf | |
| ToppCell | Somatosensory_Cortex_(S1)-Neuronal-Inh_GABAergic-i_Gaba_2-GABA_VIP_2-Inh_L2-6_VIP_VIP|Somatosensory_Cortex_(S1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 2.32e-04 | 179 | 30 | 3 | 01302505816f272243659e20d751b61a198a2fc0 | |
| ToppCell | Mid-temporal_gyrus_(MTG)-Neuronal-Inh_GABAergic-i_Gaba_3-GABA_PVALB_2|Mid-temporal_gyrus_(MTG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 2.32e-04 | 179 | 30 | 3 | 3b0f8781232e1d42b6f8913bc989a14b3f978e79 | |
| ToppCell | Somatosensory_Cortex_(S1)-Neuronal-Inh_GABAergic-i_Gaba_2-GABA_VIP_2-Inh_L1-6_VIP_RGS16|Somatosensory_Cortex_(S1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 2.32e-04 | 179 | 30 | 3 | 5bf191bdc0c32bce83ab5c38f0616e209e420e55 | |
| ToppCell | primary_auditory_cortex_(A1C)-Neuronal-Glutamatergic_Excit-Glut_C-D_(RORB)-Glut_C_(IT_L4_RORB)-Exc_L2-4_RORB_GRIK1|primary_auditory_cortex_(A1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 2.36e-04 | 180 | 30 | 3 | fd8c2059fcb382ffbfe19e598e37a49e1d5637b5 | |
| ToppCell | ASK428-Immune-NK_cell|ASK428 / Donor, Lineage and Cell class of Lung cells from Dropseq | 2.36e-04 | 180 | 30 | 3 | 857d09446e3e6737e83d0f10bfda2ba282d5ba75 | |
| ToppCell | PBMC_fresh-frozen-Mild-Moderate_progression_d12-25-Lymphocytic-Lymphocytic_T-CD8-positive,_alpha-beta_T_cell-T_CD8_c03-GZMK|Mild-Moderate_progression_d12-25 / Compartment, severity and other cell annotations on 10x 3' data (130k) | 2.40e-04 | 181 | 30 | 3 | 12ff56fa2949c8d53360cdf2cacfd326e65b54aa | |
| ToppCell | Somatosensory_Cortex_(S1)-Neuronal-Inh_GABAergic-i_Gaba_2-GABA_VIP_2-Inh_L1-3_VIP_ZNF322P1|Somatosensory_Cortex_(S1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 2.40e-04 | 181 | 30 | 3 | 062f00736eed96e4f4327615d093558dd7d82b20 | |
| ToppCell | Somatosensory_Cortex_(S1)-Neuronal-Inh_GABAergic-i_Gaba_2|Somatosensory_Cortex_(S1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 2.44e-04 | 182 | 30 | 3 | 420a8fd30543e37a66ba0786215d056d308660d0 | |
| ToppCell | Primary_Motor_Cortex_(M1)-Neuronal-Inh_GABAergic-i_Gaba_3-GABA_PVALB_1-Inh_L5_PVALB_CNTNAP3P2|Primary_Motor_Cortex_(M1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 2.48e-04 | 183 | 30 | 3 | 121791ef84e7ce377ed6f5b7953af8865e04958e | |
| ToppCell | Somatosensory_Cortex_(S1)-Neuronal-Inh_GABAergic-i_Gaba_2-GABA_VIP_2|Somatosensory_Cortex_(S1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 2.52e-04 | 184 | 30 | 3 | 32473dbdb2de66391157c5814ef34e790806e4f2 | |
| ToppCell | Primary_Visual_cortex_(V1C)-Neuronal-Inh_GABAergic-i_Gaba_1-GABA_L1_LAMP5-Inh_L5-6_LAMP5_SFTA3_(Lamp5_Lhx6_2)|Primary_Visual_cortex_(V1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 2.52e-04 | 184 | 30 | 3 | e2de27cee3ea80f9b7a9a7884ceceeaa67b3214a | |
| ToppCell | Primary_Visual_cortex_(V1C)-Neuronal-Inh_GABAergic-i_Gaba_3-GABA_PVALB_1-Inh_L2-4_PVALB_C8orf4|Primary_Visual_cortex_(V1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 2.52e-04 | 184 | 30 | 3 | 2ba98708dfd7f1b2a661578a334684094ff453ad | |
| ToppCell | Mid-temporal_gyrus_(MTG)-Neuronal-Inh_GABAergic-i_Gaba_2-GABA_VIP_2-Inh_L1-3_VIP_ZNF322P1|Mid-temporal_gyrus_(MTG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 2.56e-04 | 185 | 30 | 3 | 0b5a0df58ae2ad8261f40f152775747af4f3937a | |
| ToppCell | Primary_Visual_cortex_(V1C)-Neuronal-Inh_GABAergic-i_Gaba_2|Primary_Visual_cortex_(V1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 2.56e-04 | 185 | 30 | 3 | bdfa8c284bbc5e85c806327fbb7778cf16242a38 | |
| ToppCell | COVID-19_Moderate-NK_activated|World / disease group, cell group and cell class | 2.60e-04 | 186 | 30 | 3 | ff8f32f69516bf785224fa12f8139a95359b0279 | |
| ToppCell | 10x_3'_v3-thymus_(10x_3'_v3)-lymphocytic-innate_lymphocytic-mature_NK_T_cell|thymus_(10x_3'_v3) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type | 2.60e-04 | 186 | 30 | 3 | c984e5729958237b101df96d1c89a236faacded6 | |
| ToppCell | COVID-19-Heart-EC_2|Heart / Disease (COVID-19 only), tissue and cell type | 2.64e-04 | 187 | 30 | 3 | 40ffc06a3e3251d9b12da390210d3e045af7537a | |
| ToppCell | Control-T_cells|Control / group, cell type (main and fine annotations) | 2.64e-04 | 187 | 30 | 3 | f4e8e0eba58da89b56587667555a5d4754e108c7 | |
| ToppCell | droplet-Kidney-KIDNEY-1m-Endothelial-Pecam____kidney_capillary_endothelial_cell|Kidney / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.68e-04 | 188 | 30 | 3 | 51c6796a9488c056a10d048082015342c2e037f9 | |
| ToppCell | droplet-Kidney-KIDNEY-1m-Endothelial-kidney_capillary_endothelial_cell|Kidney / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.68e-04 | 188 | 30 | 3 | b651024d58ed1bcfe0d80b21755f8bf709eda81f | |
| ToppCell | primary_auditory_cortex_(A1C)-Neuronal-Inh_GABAergic-i_Gaba_2-GABA_VIP_2|primary_auditory_cortex_(A1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 2.68e-04 | 188 | 30 | 3 | 6ee3f8f94ea7bdf652c9575fc65bff08070093a4 | |
| ToppCell | Primary_Motor_Cortex_(M1)-Neuronal-Inh_GABAergic-i_Gaba_2-GABA_VIP_2|Primary_Motor_Cortex_(M1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 2.68e-04 | 188 | 30 | 3 | c66fccdfe68760b8c3efca77e3c25966dc9a8a5f | |
| ToppCell | (0)_NK_CD160pos|World / Spleen cell shreds - cell class (v1) and cell subclass (v1) | 2.72e-04 | 189 | 30 | 3 | 713991025bb92d38cb0507ff01fd91b48c8af45a | |
| ToppCell | COVID-19-T_cells-CD8+_T_cells|COVID-19 / group, cell type (main and fine annotations) | 2.72e-04 | 189 | 30 | 3 | 2c018d6120f65f0b2704b483bc9da1c0984872e3 | |
| ToppCell | COVID-19-T_cells-NK_cells|COVID-19 / group, cell type (main and fine annotations) | 2.72e-04 | 189 | 30 | 3 | b699152dfbb8cd8ed724e1e5a51838f29b681b62 | |
| ToppCell | Control-T_cells-CD4+_T_cells|Control / group, cell type (main and fine annotations) | 2.77e-04 | 190 | 30 | 3 | 0733be5e54fe15d6d6ea51c154a95258e83f1b92 | |
| ToppCell | primary_auditory_cortex_(A1C)-Neuronal-Inh_GABAergic-i_Gaba_3-GABA_PVALB_1-Inh_L2-4_PVALB_C8orf4|primary_auditory_cortex_(A1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 2.77e-04 | 190 | 30 | 3 | 0acf1d5da68db449d8c9e70519a236ce825f9d11 | |
| ToppCell | IPF-Lymphoid-T|IPF / Disease state, Lineage and Cell class | 2.77e-04 | 190 | 30 | 3 | d57df208aaf7a5554899bb9107c80b443fd0cf93 | |
| ToppCell | ILEUM-non-inflamed|ILEUM / shred on tissue, inflammation_status, cell class(v3), cell subclass (v2) | 2.81e-04 | 191 | 30 | 3 | c4a78ef7b87ffadbb1b9b69cbfa7c164ca456f9a | |
| ToppCell | COVID-19-Myeloid-DC1|Myeloid / Condition, Lineage and Cell class | 2.81e-04 | 191 | 30 | 3 | 4be3c6287965fe3a2f109d26f68bdc2fa393f99b | |
| ToppCell | COVID-19-T_cells|COVID-19 / group, cell type (main and fine annotations) | 2.81e-04 | 191 | 30 | 3 | 7f64add931b64b8d35836fa6bee9ebab593844d3 | |
| ToppCell | Mid-temporal_gyrus_(MTG)-Neuronal-Inh_GABAergic-i_Gaba_2-GABA_VIP_2|Mid-temporal_gyrus_(MTG) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 2.85e-04 | 192 | 30 | 3 | 6a252e298f8a454623fa9c1c893a7a45a886d694 | |
| ToppCell | Control-Lymphoid-T|World / Disease state, Lineage and Cell class | 2.85e-04 | 192 | 30 | 3 | 253cf4d2cf88ad8c45b73779336180840bef054b | |
| ToppCell | facs-Thymus-Epithelium-24m-Endothelial|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.85e-04 | 192 | 30 | 3 | 39afea574725ce0c67afdd79facdb34f819a828d | |
| ToppCell | systemic_lupus_erythematosus-flare-Lymphocytic_T-CytoT_GZMH+-male|systemic_lupus_erythematosus / PBMC cell types (v2) per disease, treatment status, and sex | 2.85e-04 | 192 | 30 | 3 | fdc741e1846cfd8ed741b160e3c611c310c5d36d | |
| ToppCell | COPD-Lymphoid-T|World / Disease state, Lineage and Cell class | 2.85e-04 | 192 | 30 | 3 | eb4909574fb5fc91399463523e2737095773200a | |
| ToppCell | facs-Thymus-Epithelium-24m-Endothelial-endothelial_cell|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.85e-04 | 192 | 30 | 3 | 597db951b1fbc37db22134c3d27d3ec4ceaa85f7 | |
| ToppCell | IPF-Lymphoid-T|World / Disease state, Lineage and Cell class | 2.85e-04 | 192 | 30 | 3 | b25ba1f3bc842c22602b2aeed3b1b5082863e4fa | |
| ToppCell | facs-Thymus-Epithelium-24m-Endothelial-endothelial_cell|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.85e-04 | 192 | 30 | 3 | bc275a9eccb1c7a46fd58b15ca5acdd9f7495842 | |
| ToppCell | 3'-GW_trimst-1.5-SmallIntestine-Mesenchymal-fibroblastic-Stromal_3_(KCNN3+)|GW_trimst-1.5 / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 2.90e-04 | 193 | 30 | 3 | 7cd9671e0ac64f7f3607f564485c63abbb7e7a63 | |
| ToppCell | systemic_lupus_erythematosus-treated-Lymphocytic_T-CD8-positive,_alpha-beta_T_cell|systemic_lupus_erythematosus / PBMC cell types (v2) per disease, treatment status, and sex | 2.90e-04 | 193 | 30 | 3 | 6e1498153a7766c03fddbda1701dbf1596d21736 | |
| ToppCell | Control-Lymphoid-T|Control / Disease state, Lineage and Cell class | 2.90e-04 | 193 | 30 | 3 | af928046ccd1ca874be1534aef6ca7f27d90bc46 | |
| ToppCell | Children_(3_yrs)-Immune-T_lymphocyte|Children_(3_yrs) / Lineage, Cell type, age group and donor | 2.90e-04 | 193 | 30 | 3 | b9769b45125d2244afe53f9f71c92c04ddccf980 | |
| ToppCell | systemic_lupus_erythematosus-treated-Lymphocytic_T-CD8-positive,_alpha-beta_T_cell-female|systemic_lupus_erythematosus / PBMC cell types (v2) per disease, treatment status, and sex | 2.90e-04 | 193 | 30 | 3 | fce4f805e53669acb4c188f87ac7d84408c0c218 | |
| ToppCell | kidney_cells-Renal_AKI_(acute_kidney_injury)-Epithelial-Intermediate_tubule_epithelial_cell-kidney_loop_of_Henle_thin_descending_limb_epithelial_cell-Descending_Thin_Limb_Cell_Type_2|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group | 2.94e-04 | 194 | 30 | 3 | 8ddcaaf24cee6e30d5be52c0cbf778cfba309c53 | |
| ToppCell | PBMC_fresh-frozen-Severe-critical_progression_d12-22_with-steroid-Lymphocytic-Lymphocytic_T-CD8-positive,_alpha-beta_T_cell-T_CD8_c05-ZNF683|Severe-critical_progression_d12-22_with-steroid / Compartment, severity and other cell annotations on 10x 3' data (130k) | 2.94e-04 | 194 | 30 | 3 | 24837a27b0041fe8c348225fa8b09b127d743603 | |
| ToppCell | COVID-19-lung-NK_cells|COVID-19 / Disease (COVID-19 only), tissue and cell type | 2.94e-04 | 194 | 30 | 3 | 4c92f18e0a34fb50630d4b260eaf179202508b6d | |
| ToppCell | control-Lymphocytic-CD8_T_cells|Lymphocytic / Cohort 2 (Rhapsody WB + PBMC) with disease condition, lineage and cell classs | 2.99e-04 | 195 | 30 | 3 | 55b9052336cab3e769a126ecaeef267d8e7bcaa8 | |
| ToppCell | facs-Aorta-Heart-3m-Endothelial-aorta_endothelial_cell|Aorta / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.99e-04 | 195 | 30 | 3 | 3969b8d5fcec8ef1831531a781f7bbcebab5a4ba | |
| ToppCell | COVID-19-lung-NK_cells|lung / Disease (COVID-19 only), tissue and cell type | 2.99e-04 | 195 | 30 | 3 | 3b716ec7acc9a37af6bf40e711a539ce58d74aa4 | |
| ToppCell | systemic_lupus_erythematosus-flare-Lymphocytic_T-CytoT_GZMH+|systemic_lupus_erythematosus / PBMC cell types (v2) per disease, treatment status, and sex | 2.99e-04 | 195 | 30 | 3 | 1a7c2c4cf30df435770794a989be438579bf98f2 | |
| ToppCell | COPD-Lymphoid-T|COPD / Disease state, Lineage and Cell class | 3.03e-04 | 196 | 30 | 3 | 30e53b8050d2a041f855d0e39bbd8f923c64c489 | |
| ToppCell | 5'-GW_trimst-1.5-SmallIntestine-Mesenchymal-fibroblastic-Stromal_3_(KCNN3+)|GW_trimst-1.5 / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 3.03e-04 | 196 | 30 | 3 | 308fa54385ca34e9e590967d4553b84aad96c92f | |
| ToppCell | PBMC_fresh-frozen-Severe-critical_progression_d12-22_with-steroid-Lymphocytic-Lymphocytic_ILC-NK_cell|Severe-critical_progression_d12-22_with-steroid / Compartment, severity and other cell annotations on 10x 3' data (130k) | 3.03e-04 | 196 | 30 | 3 | 08714b70ddaee7d11397c1dd4a287d412edd90f7 | |
| ToppCell | 10x_3'_v2v3-Non-neoplastic-Lymphoid-CD4/CD8-Stress_sig-Z|10x_3'_v2v3 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group | 3.03e-04 | 196 | 30 | 3 | 578afe58962a24874b99b0407a647b12e972344b | |
| ToppCell | PBMC_fresh-frozen-Mild-Moderate_convalescent_d36-51-Lymphocytic-Lymphocytic_T-CD8-positive,_alpha-beta_T_cell-T_CD8_c06-TNF|Mild-Moderate_convalescent_d36-51 / Compartment, severity and other cell annotations on 10x 3' data (130k) | 3.03e-04 | 196 | 30 | 3 | bc4628d959d76c16981ac3b943f7c3fbbba49391 | |
| ToppCell | PBMC_fresh-frozen-Severe-critical_progression_d12-22_with-steroid-Lymphocytic-Lymphocytic_ILC|Severe-critical_progression_d12-22_with-steroid / Compartment, severity and other cell annotations on 10x 3' data (130k) | 3.03e-04 | 196 | 30 | 3 | 5bcc959db7deb34d5a32d3464367d47d4945cdaf | |
| ToppCell | 10x5'-blood-Lymphocytic_T_CD8|blood / Manually curated celltypes from each tissue | 3.03e-04 | 196 | 30 | 3 | 2bf0f36af1d0934c03999dbbff3c51ae9432386d | |
| ToppCell | PBMC_fresh-frozen-Severe-critical_progression_d12-22_with-steroid-Lymphocytic-Lymphocytic_ILC-NK_cell-NK_c01-FCGR3A|Severe-critical_progression_d12-22_with-steroid / Compartment, severity and other cell annotations on 10x 3' data (130k) | 3.08e-04 | 197 | 30 | 3 | f84263c5aaf3a5cd46d6e06358e8de6c6e6eaa3b | |
| ToppCell | Fetal_brain-fetalBrain_Zhong_nature-GW08-Neuronal-GABAergic_neurons|GW08 / Sample Type, Dataset, Time_group, and Cell type. | 3.08e-04 | 197 | 30 | 3 | e1a80c1aa7f7e83f5d19a40fe37db5c5a6c25685 | |
| ToppCell | COVID_non-vent-Lymphocytic-T_cell-CD8+_Memory_T_cell|COVID_non-vent / Disease condition, Lineage, Cell class and subclass | 3.08e-04 | 197 | 30 | 3 | 836061acd7f0d5de89b16f52ec679bdf09eac9db | |
| ToppCell | Brain_organoid-organoid_Paulsen_bioRxiv-6_mon-Macroglial|6_mon / Sample Type, Dataset, Time_group, and Cell type. | 3.08e-04 | 197 | 30 | 3 | 965d5a3f8c9b12cb8a8d3429702ae29ebd8c6122 | |
| ToppCell | Severe-Lymphoid-T-CD8_T|Severe / Condition, Lineage, Cell class and cell subclass | 3.08e-04 | 197 | 30 | 3 | 00d884ec591f63a345d7fd0a6b368f9da4b4c6ce | |
| ToppCell | PBMC_fresh-frozen-Mild-Moderate_convalescent_d36-51-Lymphocytic-Lymphocytic_T-CD8-positive,_alpha-beta_T_cell|Mild-Moderate_convalescent_d36-51 / Compartment, severity and other cell annotations on 10x 3' data (130k) | 3.08e-04 | 197 | 30 | 3 | a44501cac24c2f4a53b413e92bd060eed6514616 | |
| ToppCell | Brain_organoid-organoid_Paulsen_bioRxiv-6_mon-Macroglial-Astroglia|6_mon / Sample Type, Dataset, Time_group, and Cell type. | 3.08e-04 | 197 | 30 | 3 | 3f088eb29197bc575400d6dafd8083e69e4a149f | |
| ToppCell | 10x3'2.3-week_17-19-Myeloid_neutrophil-granulo-neutrophil|week_17-19 / cell types per 3 fetal stages;per 3',per 5' | 3.12e-04 | 198 | 30 | 3 | 82f6ac18c3a6487f03579b5c247844f1c115c2be | |
| ToppCell | Non-neuronal-Dividing-Radial_Glia-vRG-20|World / Primary Cells by Cluster | 3.12e-04 | 198 | 30 | 3 | bce0bc1e3f2257e0f42a1fa6e5b57cf71e4514ba | |
| ToppCell | 10x3'2.3-week_17-19-Myeloid_neutrophil-granulo|week_17-19 / cell types per 3 fetal stages;per 3',per 5' | 3.12e-04 | 198 | 30 | 3 | f870e398e996c1f28c8462d87b18f71b20c71011 | |
| ToppCell | Tracheal-NucSeq-Immune_Lymphocytic-NK-ILC-T_NK-NK|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations | 3.17e-04 | 199 | 30 | 3 | 598937913fe1f12d741fa49e23ae195a7be5cbe3 | |
| ToppCell | mLN-(0)_NK_cell-(00)_NK|mLN / shred on region, Cell_type, and subtype | 3.17e-04 | 199 | 30 | 3 | 59d8e4f57580c7273308c32e5308fc1d704b1f6d | |
| ToppCell | mLN-NK_cell-NK|mLN / Region, Cell class and subclass | 3.17e-04 | 199 | 30 | 3 | cc9836b8d18edabe8849a3e948b84d954ef68c48 | |
| ToppCell | mLN-(0)_NK_cell|mLN / shred on region, Cell_type, and subtype | 3.17e-04 | 199 | 30 | 3 | 05f5ae4c049f242131a7f59bcce4b18ed52f11be | |
| ToppCell | COVID_non-vent-Lymphocytic-ILC|COVID_non-vent / Disease condition, Lineage, Cell class and subclass | 3.17e-04 | 199 | 30 | 3 | df4f7d5be099e3e6054f3b812ccf70251664e4c0 | |
| Drug | 5-(alpha-methyl-4-bromobenzylamino)phosphonomethyl-1,4-dihydroquinoxaline-2,3-dione | 2.28e-08 | 5 | 31 | 3 | ctd:C498554 | |
| Drug | (2S*,3R*)-1-(biphenyl-4-carbonyl)piperazine-2,3-dicarboxylic acid | 2.28e-08 | 5 | 31 | 3 | ctd:C491996 | |
| Drug | 2-Aminoadipic Acid | 2.28e-08 | 5 | 31 | 3 | ctd:D015074 | |
| Drug | SDZ EAA 494 | 2.28e-08 | 5 | 31 | 3 | ctd:C065286 | |
| Drug | Naphthols | 4.56e-08 | 6 | 31 | 3 | ctd:D009284 | |
| Drug | Meperidine | 4.56e-08 | 6 | 31 | 3 | DB00454 | |
| Drug | 1,5-(diethylamino)piperidine | 4.56e-08 | 6 | 31 | 3 | CID000004025 | |
| Drug | 3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid | 7.97e-08 | 7 | 31 | 3 | ctd:C050592 | |
| Drug | Tenocyclidine | 7.97e-08 | 7 | 31 | 3 | DB01520 | |
| Drug | tetrazol-5-yl)glycine | 7.97e-08 | 7 | 31 | 3 | CID000126383 | |
| Drug | homoquinolinate | 7.97e-08 | 7 | 31 | 3 | CID003080554 | |
| Drug | S)-piperazine-2-carboxylic acid | 7.97e-08 | 7 | 31 | 3 | CID001502069 | |
| Drug | 6-chloroquinoxaline-2,3-diol | 1.27e-07 | 8 | 31 | 3 | CID000081143 | |
| Drug | ES-242-1 | 1.27e-07 | 8 | 31 | 3 | CID000131976 | |
| Drug | piperazine-2,3-dicarboxylic acid | 1.27e-07 | 8 | 31 | 3 | CID000280973 | |
| Drug | SDZ 220-581 | 1.27e-07 | 8 | 31 | 3 | CID000128019 | |
| Drug | 3alpha5betaHS | 1.27e-07 | 8 | 31 | 3 | CID000165024 | |
| Drug | neramexane | 1.27e-07 | 8 | 31 | 3 | CID006433106 | |
| Drug | L-687,414 | 1.27e-07 | 8 | 31 | 3 | CID000125556 | |
| Drug | Phenanthrenes | 1.91e-07 | 9 | 31 | 3 | ctd:D010616 | |
| Drug | 5-phosphonopentanoic acid | 3.74e-07 | 11 | 31 | 3 | CID002773807 | |
| Drug | EAB 515 | 3.74e-07 | 11 | 31 | 3 | CID000159489 | |
| Drug | o-difluorobenzene | 3.74e-07 | 11 | 31 | 3 | CID000009706 | |
| Drug | oxiracetam | 3.74e-07 | 11 | 31 | 3 | CID000004626 | |
| Drug | CI-1041 | 4.99e-07 | 12 | 31 | 3 | CID000156328 | |
| Drug | tenocyclidine | 4.99e-07 | 12 | 31 | 3 | CID000062751 | |
| Drug | Agmatine | 6.48e-07 | 13 | 31 | 3 | ctd:D000376 | |
| Drug | 1,10-diaminodecane | 6.48e-07 | 13 | 31 | 3 | CID000001317 | |
| Drug | 1c88 | 7.26e-07 | 126 | 31 | 5 | CID000444766 | |
| Drug | remacemide | 8.23e-07 | 14 | 31 | 3 | CID000060510 | |
| Drug | thiokynurenic acid | 1.03e-06 | 15 | 31 | 3 | CID003035667 | |
| Drug | ACEA-1011 | 1.03e-06 | 15 | 31 | 3 | CID000127872 | |
| Drug | argiopine | 1.26e-06 | 16 | 31 | 3 | CID000122294 | |
| Drug | 3,4,7,8-tetrahydroquinoline | 1.26e-06 | 16 | 31 | 3 | CID000094356 | |
| Drug | LY233536 | 1.26e-06 | 16 | 31 | 3 | CID000126239 | |
| Drug | metaphit | 1.26e-06 | 16 | 31 | 3 | CID000114745 | |
| Drug | 7-Cl-Thio-Kyna | 1.53e-06 | 17 | 31 | 3 | CID003035668 | |
| Drug | PRE-084 | 1.53e-06 | 17 | 31 | 3 | CID000126402 | |
| Drug | ADCI | 1.53e-06 | 17 | 31 | 3 | CID000130099 | |
| Drug | 3-hydroxyglutaric acid | 1.84e-06 | 18 | 31 | 3 | CID000181976 | |
| Drug | MNQX | 1.84e-06 | 18 | 31 | 3 | CID000130818 | |
| Drug | arcaine | 2.18e-06 | 19 | 31 | 3 | CID000002227 | |
| Drug | C22H28N2O4 | 2.18e-06 | 19 | 31 | 3 | CID000065570 | |
| Drug | IDRA 21 | 2.56e-06 | 20 | 31 | 3 | CID000003688 | |
| Drug | carbetapentane | 2.99e-06 | 21 | 31 | 3 | CID000002562 | |
| Drug | NS 102 | 3.46e-06 | 22 | 31 | 3 | CID005282252 | |
| Drug | CX516 | 3.46e-06 | 22 | 31 | 3 | CID000148184 | |
| Drug | D-G-G | 3.97e-06 | 23 | 31 | 3 | CID000444866 | |
| Drug | YM90K | 3.97e-06 | 23 | 31 | 3 | CID005486547 | |
| Drug | pentanol | 3.97e-06 | 23 | 31 | 3 | CID000006276 | |
| Drug | CGP 39653 | 4.54e-06 | 24 | 31 | 3 | CID006437837 | |
| Drug | RS)-2-chloro-5-hydroxyphenylglycine | 4.54e-06 | 24 | 31 | 3 | CID003645780 | |
| Drug | gavestinel | 5.15e-06 | 25 | 31 | 3 | CID006450546 | |
| Drug | budipine | 5.15e-06 | 25 | 31 | 3 | CID000068778 | |
| Drug | conotoxin GV | 5.38e-06 | 3 | 31 | 2 | ctd:C055407 | |
| Drug | AC1NQH9B | 5.82e-06 | 26 | 31 | 3 | CID005221504 | |
| Drug | AC1L1BL0 | 5.82e-06 | 26 | 31 | 3 | CID000001484 | |
| Drug | 2-chloropropionate | 6.54e-06 | 27 | 31 | 3 | CID000011734 | |
| Drug | SKF 10,047 | 6.54e-06 | 27 | 31 | 3 | CID000001235 | |
| Drug | L-689,560 | 6.54e-06 | 27 | 31 | 3 | CID000121918 | |
| Drug | aurintricarboxylic acid | 6.92e-06 | 91 | 31 | 4 | CID000002259 | |
| Drug | chlormethiazole | 7.32e-06 | 28 | 31 | 3 | CID000010783 | |
| Drug | aptiganel | 7.32e-06 | 28 | 31 | 3 | CID000060839 | |
| Drug | C-PP | 7.32e-06 | 28 | 31 | 3 | CID000001228 | |
| Drug | DL-Serine | 7.55e-06 | 203 | 31 | 5 | CID000000617 | |
| Drug | AC1NUW3V | 8.15e-06 | 29 | 31 | 3 | CID005462126 | |
| Drug | ketobemidone | 8.15e-06 | 29 | 31 | 3 | CID000010101 | |
| Drug | LY293558 | 9.05e-06 | 30 | 31 | 3 | CID000127894 | |
| Drug | AC1L32TU | 9.05e-06 | 30 | 31 | 3 | CID000107831 | |
| Drug | cis-2,3-piperidine dicarboxylic acid | 9.05e-06 | 30 | 31 | 3 | CID000001226 | |
| Drug | GYKI 53655 | 9.05e-06 | 30 | 31 | 3 | CID000126757 | |
| Drug | LY235959 | 1.00e-05 | 31 | 31 | 3 | CID000131938 | |
| Drug | 4-methylglutamic acid | 1.00e-05 | 31 | 31 | 3 | CID000005365 | |
| Drug | eliprodil | 1.00e-05 | 31 | 31 | 3 | CID000060703 | |
| Drug | NPC 12626 | 1.00e-05 | 31 | 31 | 3 | CID000108099 | |
| Drug | Poly C | 1.07e-05 | 4 | 31 | 2 | ctd:D011066 | |
| Drug | indole-2-carboxylic acid | 1.10e-05 | 32 | 31 | 3 | CID000072899 | |
| Drug | remifentanil | 1.10e-05 | 32 | 31 | 3 | CID000060814 | |
| Drug | NSC-673323 | 1.10e-05 | 32 | 31 | 3 | CID000384101 | |
| Drug | alpha-methyl-4-carboxyphenylglycine | 1.10e-05 | 32 | 31 | 3 | CID000001222 | |
| Drug | pentamidine | 1.21e-05 | 33 | 31 | 3 | CID000004735 | |
| Drug | 1-aminoindan-1,5-dicarboxylic acid | 1.21e-05 | 33 | 31 | 3 | CID000002071 | |
| Drug | BMY 14802 | 1.21e-05 | 33 | 31 | 3 | CID000108046 | |
| Drug | 6,7-dinitroquinoxaline | 1.21e-05 | 33 | 31 | 3 | CID002724608 | |
| Drug | D-CPPene | 1.33e-05 | 34 | 31 | 3 | CID006435801 | |
| Drug | norethisterone oenanthate | 1.42e-05 | 109 | 31 | 4 | CID000019688 | |
| Drug | kainite | 1.45e-05 | 35 | 31 | 3 | CID000164810 | |
| Drug | 3-7a | 1.58e-05 | 36 | 31 | 3 | CID011987860 | |
| Drug | PhTX-343 | 1.58e-05 | 36 | 31 | 3 | CID000159548 | |
| Drug | 3-bromo-7-nitroindazole | 1.58e-05 | 36 | 31 | 3 | CID000001649 | |
| Drug | C6H12NO5P | 1.58e-05 | 36 | 31 | 3 | CID000104962 | |
| Drug | glutamic acid diethyl ester | 1.58e-05 | 36 | 31 | 3 | CID000073960 | |
| Drug | gacyclidine | 1.58e-05 | 36 | 31 | 3 | CID000176265 | |
| Drug | R,S)-AMPA | 1.58e-05 | 36 | 31 | 3 | CID000001221 | |
| Drug | gamma-Glu-Gly | 1.72e-05 | 37 | 31 | 3 | CID000100099 | |
| Drug | rilmenidine | 1.72e-05 | 37 | 31 | 3 | CID000068712 | |
| Drug | benzyloxyaspartate | 1.72e-05 | 37 | 31 | 3 | CID004133412 | |
| Drug | GAMs | 1.87e-05 | 38 | 31 | 3 | CID000002935 | |
| Drug | L-BMAA | 1.87e-05 | 38 | 31 | 3 | CID000028558 | |
| Drug | CGS 19755 | 1.87e-05 | 38 | 31 | 3 | CID000068736 | |
| Disease | developmental disorder of mental health (implicated_via_orthology) | 1.37e-05 | 49 | 28 | 3 | DOID:0060037 (implicated_via_orthology) | |
| Disease | Schizophrenia | 1.43e-05 | 883 | 28 | 7 | C0036341 | |
| Disease | arabinose measurement | 1.82e-05 | 7 | 28 | 2 | EFO_0021030 | |
| Disease | HDL cholesterol change measurement | 2.37e-04 | 24 | 28 | 2 | EFO_0007805 | |
| Disease | systemic mastocytosis | 2.57e-04 | 25 | 28 | 2 | MONDO_0016586 | |
| Disease | epilepsy (implicated_via_orthology) | 4.90e-04 | 163 | 28 | 3 | DOID:1826 (implicated_via_orthology) | |
| Disease | systemic scleroderma, rheumatoid arthritis, myositis, systemic lupus erythematosus | 5.98e-04 | 38 | 28 | 2 | EFO_0000685, EFO_0000717, EFO_0000783, MONDO_0007915 | |
| Disease | myositis | 6.30e-04 | 39 | 28 | 2 | EFO_0000783 | |
| Disease | triglycerides in large LDL measurement | 7.65e-04 | 43 | 28 | 2 | EFO_0022319 | |
| Disease | monokine induced by gamma interferon measurement | 1.12e-03 | 52 | 28 | 2 | EFO_0008236 | |
| Disease | triglycerides in LDL measurement | 1.30e-03 | 56 | 28 | 2 | EFO_0022320 | |
| Disease | rheumatoid arthritis, ACPA-positive rheumatoid arthritis, rheumatoid factor seropositivity measurement | 1.64e-03 | 63 | 28 | 2 | EFO_0000685, EFO_0007791, EFO_0009459 | |
| Disease | Colorectal Neoplasms | 2.25e-03 | 277 | 28 | 3 | C0009404 |
| Peptide | Gene | Start | Entry |
|---|---|---|---|
| TIDVYMVMVKCWMID | 946 | Q15303 | |
| CMYTTLIAMTGWYMD | 196 | Q9H6U8 | |
| VMMTAIISFFVCWMP | 246 | Q49SQ1 | |
| MSRSMPLFMTLAWIY | 636 | O95477 | |
| MYFMTMIVSLAAVAW | 136 | Q15041 | |
| EKMTMMAHQYPSWIF | 31 | Q6ZTQ3 | |
| MSVIMICMFLVAWSP | 241 | O14718 | |
| MIWEYSVLIIVMACM | 116 | Q9Y2R2 | |
| MWGAYSVLAMAPTMI | 101 | Q8N9R6 | |
| KYMTLMSPRVCWIMV | 131 | A6NM03 | |
| FMYPEMGSCMWFPAK | 736 | Q8IVU3 | |
| MSLMVISMACVGFFW | 1 | Q14952 | |
| MLVTMFGWFTMVISY | 206 | Q96PB8 | |
| VSHFMPVMFSLTWDM | 371 | P49411 | |
| IMSKAAYMPMAASSW | 136 | Q9NQN1 | |
| MLMGCVVNYLVFCWM | 206 | Q9H5J4 | |
| MMTSWAIVCDVWYMP | 356 | Q53EU6 | |
| GAAYAWMMCVFTVVM | 621 | Q5T3F8 | |
| WMMCVFTVVMTYSIT | 626 | Q5T3F8 | |
| FVIEHMMPLCMVISW | 701 | Q9BZC7 | |
| MMPLCMVISWVYSVA | 706 | Q9BZC7 | |
| MMCAVYGWTEEMAFS | 866 | Q05BV3 | |
| MMDIYVCLKRPSWMV | 1 | P42702 | |
| MFYAPWCSMCKRMMP | 176 | Q14554 | |
| MMTIRFWYCMEHSKP | 5291 | Q8WXH0 | |
| IWMESMWCMVYLCSP | 281 | O75343 | |
| WEIKMTSPVYGTDMM | 151 | Q6PJ21 | |
| TWMFFFMMCVAERTY | 541 | Q9UMS5 | |
| PYWMAPEVVMCETMK | 196 | O94804 | |
| ASDWPLMIFYMVMCI | 211 | Q96K49 | |
| EPFSASVWVMMFVML | 551 | Q12879 | |
| YSPAVWVMMFVMCLT | 551 | Q14957 | |
| YSPAVWVMMFVMCLT | 581 | O15399 |